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Abstract
The hepatic stellate cell (HSC) is the primary cell type in the liver responsible for excess collagen
deposition during fibrosis. Following a fibrogenic stimulus, the cell changes from a quiescent
vitamin A storing cell to an activated cell type associated with increased extracellular matrix
synthesis and increased cell proliferation. The phosphatidylinositol 3-kinase (PI3K) signaling
pathway has been shown to regulate several aspects of HSC activation in vitro, including collagen
synthesis and cell proliferation. Using a targeted approach to inhibit PI3K signaling specifically in
HSCs, we investigated the role of PI3K in HSCs using a rodent model of hepatic fibrosis. An
adenovirus expressing a dominant negative form of PI3K under control of the smooth muscle α-
actin (αSMA) promoter was generated (Ad-SMAdnPI3K). Transducing HSCs with Ad-
SMAdnPI3K resulted in decreased proliferation, migration, collagen expression, and several
additional profibrogenic genes, while also promoting cell death. Inhibition of PI3K signaling was
also associated with reduced activation of Akt, p70S6K, and extracellular regulated kinase (ERK)
signaling as well as reduced cyclin D1 expression. Administering Ad-SMAdnPI3K to mice
following bile duct ligation resulted in reduced HSC activation and decreased extracellular matrix
deposition, including collagen expression. A reduction in profibrogenic mediators, including
tumor growth factor – β (TGF-β), tissue inhibitor of metalloproteinase – 1 (TIMP-1), and
connective tissue growth factor (CTGF) was also noted. However, liver damage, assessed by
alanine aminotransferase (ALT) levels, was not reduced.
Conclusion—Inhibition of PI3K signaling in HSCs during active fibrogenesis inhibits
extracellular matrix (ECM) deposition, including synthesis of type I collagen, and reduces
expression of profibrogenic factors. These data suggest that targeting PI3K signaling in HSCs may
represent an effective therapeutic target for hepatic fibrosis.
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Introduction
Liver fibrosis represents a wound healing process in response to a variety of acute and
chronic stimuli, including ethanol, viral infections, cholestasis, and metabolic diseases (1,2).
Characterized by excess synthesis and deposition of extracellular matrix (ECM), fibrosis
disrupts the normal architecture of the liver leading to organ dysfunction, which can
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progress to cirrhosis and ultimately organ failure if left untreated. Currently, few therapeutic
strategies exist to treat liver fibrosis.
The hepatic stellate cell (HSC) is primarily responsible for excess deposition of extracellular
matrix proteins (ECM) during fibrosis. Following a fibrogenic stimulus, HSCs lose their
retinoid stores, proliferate, express smooth muscle α-actin (αSMA), and produce large
amounts of extracellular matrix proteins, including type I collagen. Phosphatidylinositol 3-
kinase (PI3K) is a key signaling molecule composed of an 85-kDa regulatory subunit and a
110-kDa catalytic subunit which is recruited to and activated by the activated PDGF
receptor following HSC activation and growth factor stimulation (3). The importance of
PI3K signaling in HSCs has been established as blocking PI3K activity, using either
pharmacological (LY294002) or genetic approaches, inhibits HSC proliferation and collagen
gene expression, a process involving interruption of key downstream signaling pathways,
including Akt and P70S6K (4,5). Activation of Akt is associated with HSC proliferation and
α1(I) collagen transcription and translation (4,6–8). Likewise, interruption of the p70S6K/
mTOR signaling suppresses HSC proliferation. Therefore, interruption of PI3K signaling is
capable of suppressing key components of HSC activation and proliferation and may
represent a therapeutic target for treating hepatic fibrosis.
Since αSMA expression is induced following HSC activation, we developed an αSMA
driven expression vector to direct expression of a dominant negative form of PI3K to
prevent HSC proliferation and collagen expression in activated HSCs. We demonstrate that
inhibition of PI3K signaling in vivo, specifically in HSCs, dramatically attenuates
experimentally induced hepatic fibrosis in mice.
Materials and Methods
Adenovirus Preparation
The dnPI3K coding sequence was amplified from Ad-dnPI3K (9) using PCR with a forward
primer 5′-gatcatgatcggatccccaccatgtacccatacgatgttccaga-3′, containing the HA-tag (bold),
and a reverse primer 5′-gatcatgatcggatcctcatcgcctctgctgcgcgt-3′. The amplified product was
digested with Bam HI and cloned into the Bam HI site in the pDNR plasmid (BD
Bioscience, San Jose, CA). The insert was sequenced to assess the orientation of the insert
and the correct sequence. The αSMA promoter was amplified from the pSMP8 plasmid (10)
using forward primer 5′-gatcatgatcgaattcacaccataaaacaagtgcatgag-3′ and reverse primer 5′-
gatcatgatcgaattcagctgcaccagcgtctcagg-3′ and the PCR product cloned into the pTOPO
plasmid (Invitrogen, Calsbad, CA). The αSMA promoter was excised from the pTOPO
plasmid using Eco RI and cloned into the Eco RI site in dnPI3K-pDNR upstream of the
dnPI3K insert. Sequencing confirmed orientation and integrity of the insert. The
recombinant adenovirus was generated using the BD Adeno-x Expression System
Promoterless Vector (BD Bioscience, San Jose, CA) according to the manufacturers’
protocol. HSCs transduced with the recombinant adenovirus expressed the HA-tag, as
assessed by Western blot analysis. Hepatocytes, endothelial cells, and Kupffer cells did not
express the HA-tag when transduced by Ad-SMAdnPI3K, thus confirming cell specific
expression (data not shown).
Hepatic Stellate Cell Isolation
Mouse HSCs were isolated as previously described (11,12) from pCOL9GFP-HS4,5
transgenic mice (collagen promoter-driven GFP transgenic mice) on a BALB/c background
which have been described previously (13). Isolated HSCs were cultured in DMEM
supplemented with 10% FBS in a 95% air − 5% CO2 atmosphere. Hepatocyte, endothelial
cell, and Kupffer cell isolation procedures are provided in supplementary materials. All
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animal procedures were performed under the guidelines set by the University of North
Carolina Institutional Animal Care and Use Committee and are in accordance with those set
by the National Institute of Health.
GFP Quantification
HSCs from pCol9GFP-HS4,5 mice were plated in 6-well plates (2 × 105 cells/well). After 5
days, cells were transduced with Ad-SMAdnPI3K, Ad-βgal, or no virus. After 12 hr, the
medium was changed to media containing 10% FBS. After 48 hr, plates were scanned for
GFP expression and quantified by phosphorimager analysis according to the recommend
protocol of the manufacturer (GE Healthcare, Piscataway, NJ).
Fibrosis Model
pCol9GFP-HS4,5 transgenic mice on a BALB/c background were subjected to double
ligation of the common bile duct (BDL) (14). Sham-treated animals underwent the same
procedure without ligation. Some mice were administered carbon tetrachloride (CCl4) to
induce fibrosis with specific procedures provided in supplementary materials. All
procedures were in accordance and approved by the Institutional Animal Care and Use
Committee guidelines at the University of North Carolina at Chapel Hill. Ad-SMAdnPI3K,
1×109 PFU, was administered 4 days following BDL via tail vein injection. Mice were
sacrificed 9 or 18 days after BDL, and blood and liver samples were harvested.
Assessment of Apoptosis
In vitro, cell death was determined by propidium iodide (PI, Sigma, St. Louis, MO) and
Hoechst 33342 (Sigma, St. Louis, MO) double fluorescent staining. HSCs were isolated
from pCol9GFP-HS4,5 transgenic mice and cultured in 6-well plates. After 5 days in
culture, HSCs were transduced with Ad-SMAdnPI3K, Ad-βgal, no virus, as above. After 24
hr, the cells were incubated with Hoechst (1 µg/ml) and PI (5 µg/ml) for 20 min.
Afterwards, cells were visualized by fluorescent microscopy. Paraffin embedded liver
sections were stained for DNA fragmentation using the In Situ Cell Death Detection Kit,
TMR red (Roche, Indianapolis, Indiana) according to the manufacturers’ recommendations.
Histological Analysis and Immunohistochemistry
Portions of the liver were collected at the time of sacrifice and fixed in 10% buffered
formalin for 24 hr at 4°C. Expression of αSMA was determined in paraffin-embedded
sections by immunohistochemistry as previously described (15). For fibrosis, liver sections
were stained with Picrosirius Red (Sigma, St. Louis, MO) as previously described (15). For
immunofluorescent staining, liver specimens were fixed using 4% paraformaldehyde for 16
hr at 4° C, incubated in PBS containing 30% sucrose 24 hr, then frozen at −80°C in OCT
Compound (Sakura Finetek USA, Inc. Torrance, CA). Sections were incubated with
monoclonal antibody to HA (1:100; Cell Signaling, Danvers, MA) using the MOM kit
(Vector Laboratories, Burlingame, CA) and Alexa Fluor 546 Streptavidin (Invitrogen) used
for visualization. Hepatic GFP expression was assessed using frozen tissue sections and
viewed by fluorescent microscopy. For triple staining, PFA fixed frozen sections were
stained with anti-GFP (chicken polyclonal; Aves Labs, Inc), anti-HA (mouse monoclonal),
and anti-Desmin (rabbit polyclonal; Thermo Scientific) all at a dilution of 1:100. For
visualization, goat anti-chicken conjugated to FITC (to stain GFP), goat-anti-rabbit
conjugated to AlexaFluor 350 (to stain Desmin), and goat anti-mouse conjugated to
AlexaFluor 546 (to visualize HA) were incubated on the sections for 30 minutes at room
temperature. For immunofluorescence cell staining, 24 hr after Ad-SMAdnPI3K
transduction (MOI: 300), HSCs were fixed with 4% paraformaldehyde and −20°C methanol
(10 min, room temperature). The cells were then incubated with anti-HA antibody 1:100
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using the MOM Kit. Sirius red-positive area, αSMA-positive area, and GFP-positive area
were quantified using Image J software (NIH Image; http://rsb.info.nih.gov/ij/) from 5
random non-overlapping 100× fields for each animal with 6 animals assessed in each group.
Antibodies
Protein extracts were prepared from liver tissue (50 µg) or cultured HSCs (20 µg) using
RIPA buffer and separated on 8–16% Tris-glycine gels and transferred to PVDF membranes
as previously described (16). Antibodies against phospho-PI3K (Tyr458), PI3K, phospho-
AktSer473, Akt, phospho-p70S6K(Thr421/Ser424), p70S6K, phospho-Erk (Thr202/Tyr204), Erk,
Cyclin D1, CD31, HA-Tag (1:1000; all from Cell Signaling), αSMA (1:5000; Sigma),
albumin (1:5000; ICN), F4/80 (1:1000; Serotec), and β-Actin (1:1000; Sigma) were used for
western blot procedures. incubated overnight at 4°C in Tris-buffered saline containing
0.05% Tween-20 (TTBS) and 5% nonfat dry milk. Appropriate horseradish peroxidase
conjugated secondary antibodies diluted 1:2,000–5,000 in TTBS + 5% nonfat dry milk were
then incubated with blots for 1 hr at room temperature. Antibody staining was visualized by
enhanced chemiluminescence (ECL plus, Amersham, Indianapolis, IN) exposed to film.
Band density was quantified from digital images using Image J software.
Other methods
Procedures for cell isolation, proliferation, and migration, hydroxyproline and alanine
aminotransferase assay, western blotting, and RT-PCR are provided in supplementary
materials.
Statistical analysis
All data are presented as means ± SEM (standard error of the mean). Differences between
Ad-SMAdnPI3K group and control groups were assessed by unpaired Student’s t-test. P-
values <0.05 were considered statistically significant.
Results
Inhibition of PI3K signaling reduces cell proliferation and migration in isolated HSCs
To determine the role of PI3K signaling in HSCs in vivo, we constructed an adenovirus that
allows for HSC specific expression of a dominant negative form of PI3K (9) using the
αSMA promoter (10). This recombinant adenovirus expressed the HA-tag in HSCs, but not
in hepatocytes, Kupffer cells, or endothelial cells (Figure 1A). In isolated HSCs, αSMA
expression was first detected following 2 days in culture (data not shown). We, therefore,
transduced isolated HSCs with Ad-SMAdnPI3K at Day 2 and noted weak expression of the
HA-tag one day after viral transduction, which progressively increased by 5 days in culture
(data not shown). Therefore, for our in vitro studies, we transduced HSCs after 4 days in
culture to assure high levels of expression of HA-dnPI3K from the αSMA promoter.
Previous studies have shown that PI3K positively regulates rat HSC proliferation (4). To
confirm that similar effects occur in murine HSCs, mouse HSCs were isolated and cultured
for 4 days. Cells were left untreated or transduced with Ad-βgal or Ad-SMAdnPI3K in
serum free media for 48 hours. Cell proliferation was stimulated using media containing
10% FCS and cells monitored for 72 hr. Control cells, or cells transduced with Ad-βgal,
showed similar increases in growth rate during the experimental time period; however, cells
transduced with Ad-SMAdnPI3K showed a significant reduction in cell numbers, compared
to Ad-βgal transduced cells (Figure 1B).
To determine whether PI3K signaling influences HSC migration, a wound assay was
performed and the distance cells migrated from the wound was assessed following a 24 hr
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culture period. Control HSCs or cells transduced with Ad-βgal showed similar migratory
responses; however, cells transduced with Ad-SMAdnPI3K showed a significant reduction
in cell migration, compared to control Ad-βgal transduced cells (Figure 1C).
Inhibition of PI3K decreases expression of α1(I) collagen in HSCs mediated in part by
inhibiting gene transcription
We first examined the expression pattern of the HA-tag present on dnPI3K and GFP, a
marker for collagen expression, in HSCs from pCol9GFP-HS4,5 transgenic mice transduced
with Ad-SMA-dnPI3K. Some cells expressed only GFP, other cells only expressed the HA-
tag; however, only a few cells expressed both the HA-tag and GFP (Figure 1D). This result
is similar to that previously reported where HSCs express either αSMA or collagen, with
only a few cells expressing both genes (10).
To confirm that blocking PI3K also inhibits α1(I) collagen gene expression in murine HSCs,
similar to that shown in rat HSCs (4), we examined the effect of Ad-SMAdnPI3K on
collagen expression in HSCs from pCol9GFP-HS4,5 transgenic mice. HSCs were either left
untreated or transduced with Ad-βgal or Ad-SMAdnPI3K after 5 days in culture. A
significant reduction in GFP fluorescence, a marker for collagen expression in these cells,
was observed following viral transduction with Ad-SMAdnPI3K (Figures 1E); a similar
reduction in α1(I) collagen mRNA expression was also observed (Figure 1F). Therefore,
blocking PI3K activity in HSCs inhibits α1(I) collagen gene expression, at least partially at
the transcriptional level.
Inhibiting PI3K induces cell death in murine HSCs
Since HSC proliferation was reduced when PI3K activity was blocked (Figure 1B), we
examined whether this inhibition is associated with increased cell death. HSCs were isolated
and cultured for 5 days, then transduced with Ad-βgal or Ad-SMAdnPI3K. Transduction
with Ad-SMAdnPI3K markedly increased propidium iodide staining, compared to cells
transduced with Ad-βgal (Figure 2 A–F). Therefore, inhibition of PI3K activity in activated
HSCs promoted membrane permeability and nuclear envelope disruption, processes
associated with cell death.
Expression of genes associated with a fibrogenic response is reduced in HSCs following
inhibition of PI3K signaling
Since inhibiting PI3K activity reduced collagen gene expression in HSCs, we examined the
effect of PI3K inhibition on the expression of several other pro-fibrogenic genes. HSCs were
cultured for 5 days, then either left untreated or transduced with Ad-SMAdnPI3K or Ad-
βgal. After 48 hr, mRNA expression of TGF-β, αSMA, TIMP-1, CTGF were significantly
reduced in cells transduced with Ad-SMAdnPI3K, compared to Ad-βgal transduced cells
(Figure 2G). In contrast, expression of PPARγ was increased 2.3-fold (Figure 2G). These
findings correlate with a reduced fibrogenic response of the activated HSC when PI3K
signaling is interrupted.
Inhibition of PI3K signaling in activated HSCs blocks activation of Akt and p70S6K
signaling and cyclin D1 expression
To examine a potential mechanism by which inhibition of PI3K signaling may mediate an
anti-fibrogenic response, we assessed the effects of blocking PI3K on ERK, PI3K, Akt, and
p70S6K signaling pathways, known to influence the fibrogenic response in HSCs. Day 5
HSCs were transduced with Ad-βgal or Ad-SMAdnPI3K, serum starved for 24 hours, then
stimulated with 10% serum and activation of PI3K and MAPK signaling analyzed. Increased
phosphorylation of the PI3K p85 subunit was observed after 30 min in both PBS and Ad-
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βgal treated cells (Figure 3A). In contrast, phosphorylation of PI3K, Akt, and p70S6K was
completely blocked in cells transduced with Ad-SMAdnPI3K, but not in PBS treated or Ad-
βgal transduced cells. Phosphorylation of Erk was only modestly attenuated by Ad-
SMAdnPI3K (Figure 3A).
To investigate a potential mechanism for reduced HSC proliferation when PI3K signaling is
blocked, we examined the influence of PI3K signaling on cyclin D1 expression, previously
shown to regulate HSC proliferation (17,18). Isolated HSCs were cultured for 5 days,
transduced with Ad-βgal or Ad-SMAdnPI3K, then serum starved for 48 hr. Cells were then
stimulated to proliferate using 10% serum for 24 hours and cyclin D1 gene expression
assessed. Control cells and cells transduced with Ad-βgal showed increased cyclin D1
expression over the 24 hr time period (Figure 3B). In contrast, cells transduced with Ad-
SMAdnPI3K failed to induce cyclin D1 expression (Figure 3B), thus demonstrating that
PI3K induces cyclin D1 expression in activated HSCs, which is partially responsible for
inducing HSC proliferation in activated HSCs.
Expression of αSMA driven dnPI3K in experimentally induced hepatic fibrosis
To examine cell specific expression of Ad-SMAdnPI3K during experimentally induced liver
fibrosis, pCol9GFP-HS4,5 transgenic mice underwent BDL and 4 days later were
administered PBS or 1×109 PFU of either Ad-βgal or Ad-SMAdnPI3K. Two days following
adenovirus administration expression of HA was detected in liver extracts from mice
administered Ad-SMAdnPI3K, while no HA expression was detected in the PBS or Ad-βgal
treated animals (Figure 4A). BDL induced significant GFP expression in both PBS and Ad-
βgal treated mice; however, mice administered Ad-SMAdnPI3K showed a marked
attenuation of GFP fluorescence, indicative of reduced collagen gene expression (Figure
4B). Interestingly, GFP expression did not appreciably co-localize to expression of the HA
tag expressed by Ad-SMAdnPI3K. A discordant expression of collagen expression and
αSMA expression in activated HSCs has previously been reported (10). Since expression of
dnPI3K in cultured HSCs induced cell death (Figure 2A–F), we examined if HSC death was
induced in the Ad-SMAdnPI3K treated animals. Indeed, HSC death was increased, assessed
by TUNEL staining, in the animals in which Ad-SMAdnPI3K was administered, but not in
PBS or Ad-βgal treated animals (Figure 4C). To further assess the co-localization in vivo of
the adenovirus within HSCs, triple staining for GFP, the marker of collagen expression,
desmin, a marker of hepatic stellate cells, and HA, a marker of virus expression was
performed on day 6, two days following adenoviral administration. As shown in Figure 4D,
there is appreciable co-localization of desmin, collagen-GFP, and HA at this time point
following adenoviral administration. Given the effects of PI3K inhibition of HSC survival
both in vitro and in vivo, we chose to also look at co-localization of HA and GFP at an
earlier time-point hypothesizing that HSC death had already occurred 4 days following
adenovirus administration. Provided in Supplemental Figure 1, co-localization of HA and
GFP could be observed 1 day following adenovirus administration (Day 5 post-BDL).
Together, these data demonstrate the ability of dnPI3K driven by the αSMA promoter to be
expressed in stellate cells in vivo and induce their apoptosis within the cholestatic liver.
Inhibiting PI3K signaling attenuates hepatic αSMA expression in BDL-induced liver
fibrosis
To determine the extent of activated HSCs in the liver following BDL-induced liver fibrosis,
immunohistochemical analysis for αSMA expression, a classical marker of activated HSCs,
was performed. Induction of liver fibrosis resulted in an increase in αSMA expression in the
livers of animals treated with either PBS or Ad-βgal 9 and 18 days following BDL,
respectively (Figures 5A, 5B). Both significant interstitial and vascular αSMA expression
was observed. αSMA expression was attenuated in the Ad-SMAdnPI3K treated animals
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where the interstitial expression pattern was mostly resolved, but vascular expression
remained relatively high (Figures 5A, 5B). Western blot analysis confirmed the
immunohistochemical staining (Figure 5C).
Inhibition of PI3K signaling attenuates collagen expression and deposition following BDL
Given the profound impact of PI3K inhibition on HSC αSMA expression in vivo following
BDL, expression of collagen was examined. As shown in Figure 6A–B, Sirius red staining
was significantly reduced in Ad-SMAdnPI3K treated mice subjected to BDL for 9 or 18
days when compared to control treated or Ad-β-gal treated mice subjected to BDL.
Moreover, tissue hydroxyproline levels were significantly reduced following 18 days of
BDL in AD-SMAdnPI3K when compared to control or β-gal treated mice subjected to BDL
(Figure 6C). GFP expression was significantly reduced as was steady-state α1(I) collagen
mRNA expression following either 9 or 18 days of BDL, compared to control treated or Ad-
β-gal treated mice subjected to BDL (Figure 6D–F). Consistent with its effects in the BDL
model of liver fibrosis, administration of Ad-SMAdnPI3K reduced fibrogenesis in the
carbon tetrachloride model of liver injury and fibrosis to a similar degree (Supplemental
Figure 2). Interestingly, a dnPI3K driven by the CMV promoter, and thus expressed in all
cells, led to significant reduction in collagen gene expression (Supplemental Figure 3) in
conjunction with significant morbidity in animals in both models of liver fibrosis, a process
which could be correlated with significant reduction in functional liver mass. These data
demonstrate the ability of PI3K to support fibrogenesis and highlight important cell specific
functions of this signaling protein. Additional studies are underway to understand the
importance of PI3K in other cell types, including hepatocytes within the chronically
damaged liver.
Ad-SMAdnPI3K inhibits hepatic expression of fibrogenic genes during BDL-induced liver
fibrosis, but does not reduce liver injury
To assess the effect of Ad-SMAdnPI3K on expression of other genes associated with liver
fibrosis, we examined the expression of TGF-β, αSMA, TIMP-1, and CTGF in the livers of
animals from each experimental group. Following 9 days of BDL, expression of TGF-β,
αSMA, TIMP-1, and CTGF were all increased and all were significantly reduced in animals
administered Ad-SMAdnPI3K, but not in control animals (Figure 7A). Liver injury was also
increased in the livers of the experimental animals; however, despite a reduction in the
progression of fibrosis, ALT levels were not reduced following administration of Ad-
SMAdnPI3K (Figure 7B).
Discussion
Liver fibrosis is a key risk factor for the development of cirrhosis and chronic liver failure.
Activation of hepatic stellate cells (HSCs) is a crucial component of this process (1,2). Here,
we show the importance of PI3K signaling in the development and progression of hepatic
fibrogenesis in vivo and during HSC activation, proliferation, and pro-fibrogenic collagen
production in vitro. In doing so, a HSC specific adenoviral vector was created which
directed strong selectivity for expression in activated, smooth muscle actin positive, HSCs.
Phosphatidylinositol 3-kinase (PI3K) represents a key signaling molecule that controls many
cellular functions, such as proliferation, survival, adhesion, and migration (3,4). In the liver,
macrophage-associated PI3K activation promotes cytokine production and subsequent
hepatocyte proliferation early following partial hepatectomy (19). Hepatocyte-associated
PI3K regulates growth following a reduction in liver volume, a process involving Akt
activation. In the setting of fibrosis, PI3K is activated via PDGF receptor ligation following
carbon tetrachloride treatment and correlates with collagen production (20). In the present
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study, inhibition of PI3K activity, via a dominant negative form of PI3K within HSCs,
reduced hepatic fibrogenesis following BDL. Inhibition of fibrogenesis was associated with
reduced TGFβ expression, αSMA expression, and collagen production. Several
mechanism(s) may exist by which PI3K might promote this activation. First, PI3K induced
Akt activation leads to cell survival and proliferation. Sustained activation of Akt has been
shown to induce significant cellular proliferation, likely involving p70S6K activation and
increased cyclin D1 expression (4). This is consistent with the present study showing that
inhibition of PI3K in HSCs in vitro decreased cyclin D1 expression and reduced cellular
proliferation. Lending to the connectivity of this pathway, inhibition of PI3K in HSCs
inhibited p70S6K activation. Previous studies have shown that inhibition of the mTOR/
p70S6K pathway by rapamycin in HSCs reduces G1 to S phase progression (17). Therefore,
inhibiting PI3K, and thus its downstream signaling mediators, significantly impacts cell
growth and proliferation (21–23).
In addition to reduced proliferation, impairment of PI3K activity in HSCs was associated
with the induction of cell death. Interruption of PI3K activity in HSCs led to a substantial
increase in TUNEL staining in vivo and membrane permeability in vitro, suggesting the
induction of cell death rather than a transition back to quiescence. The mechanism(s)
promoting this response are not clear, though inhibition of MAPK pathways, specifically
Erk, could be partially responsible. Erk activation is associated with suppression of caspase
induction and mitochondrial permeability changes (24). Moreover, Akt activation suppresses
Bad function, a pro-apoptotic factor (25). Indeed, it has been postulated that clearance of
activated HSCs is a critical step in fibrosis resolution within the liver and, from data
presented here, PI3K inhibition may represent a novel mechanism for their elimination.
A third mechanism by which PI3K may function to promote the fibrogenic response is
through the regulation of pro-fibrogenic mediator production by HSCs. Interruption of PI3K
activity suppressed TGFβ and PDGF expression by HSCs in vitro and hepatic expression of
these factors during cholestasis and their production of these factors likely promotes
autocrine activation. Moreover, PI3K activation may suppress PPARγ expression. Previous
studies have demonstrated the importance of PPARγ in suppressing hepatic fibrogenesis in
vivo and HSC activation in vitro (26). In vitro, PPARγ expression is reduced as HSCs
become activated and its overexpression leads to suppression of collagen production and
αSMA expression, a process involving inhibition of p300 transactivation (27–29). In our
study, restoration of PPARγ function could be one mechanism by which PI3K inhibition
leads to suppression of collagen production and HSC activation. In sum, interruption of
PI3K activity is capable of influencing multiple cellular levels, from cell survival and
proliferation to the promotion of growth factor production, to drive hepatic fibrogenesis.
Another interesting finding in the present study was the observed heterogeneity of HSCs
both in vitro and in vivo. Previous studies by Magness et al. identified cells within the
damaged liver which expressed either αSMA, collagen, or both suggesting the potential for
either multiple cell populations with characteristics similar to HSCs (10). In the setting of
BDL, it is clear that extrahepatic myofibroblasts are recruited periportally and contribute
significantly to hepatic fibrogenesis, in the absence of significant αSMA expression (30).
For in vitro studies, however, HSCs are enriched from undamaged livers. Similar to the in
vivo studies in the BDL model, HSCs express either αSMA or collagen or both. Thus, the
use of αSMA driven dnPI3K may only function in a subset of the collagen producing cells
within the liver. Alternatively, when PI3K activity is blocked in HSCs, cell death is induced
(Figure 2A–F). Nevertheless, our approach has led to a large and significant reduction in
collagen expression and deposition, and inhibition of pro-fibrogenic growth factor
production, both in vitro and in vivo. The overall significance of multiple HSC populations,
or intermediates within this lineage, remains to be determined.
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In summary, we have demonstrated that selective inhibition of PI3K in activated HSCs, via
a αSMA-driven dominant negative form of PI3K, reduces hepatic fibrogenesis, likely
through suppression of fibrotic gene transcription, as well as through promotion of HSC
death. In vitro studies further demonstrate the ability of PI3K inhibition to suppress HSC
proliferation, migration, and pro-fibrogenic gene expression, processes which likely
involves interruption of downstream signaling molecules including Akt and p70S6K.
Furthermore, this inhibition appears to be critical for the induction of HSC death, thereby
eliminating important collagen producing cells from the liver. In addition, the current
investigation has also revealed, as previous studies would indicate, a potential heterogeneity
of collagen producing cells within the liver, specifically the presence of αSMA-negative
collagen producing cells. Finally, the current study has led to the creation and validation of
an activated HSC specific adenoviral vector which will provide a platform for future
investigation into the functions of other cellular proteins within HSCs, both in vitro and in
vivo. In conclusion, PI3K is critical for HSC activation and collagen production and, as
such, therapies directed at inhibiting PI3K, specifically in HSCs, may be useful to treat
hepatic fibrogenesis.
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Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
HSC hepatic stellate cells
PI3K phosphatidylinositol 3-kinase
αSMA smooth muscle α-actin
p70S6K p70 S6 Kinase
ERK extracellular regulated kinase
TGF-β transforming growth factor – beta
TIMP-1 tissue inhibitor of metalloproteinase
CTGF connective tissue growth factor
ALT alanine aminotransferase
ECM extracellular matrix
PDGF platelet derived growth factor
HA hemagglutinin
DMEM Dulbecco’s modified Eagles medium
FBS fetal bovine serum
PBS phosphate buffered saline
MOI multiplicity of infection
BDL bile duct ligation
βgal β-galactosidase
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GFP green fluorescent protein
PI prodidium iodide
SEM standard error of the mean
MAKP mitogen activated protein kinase
PPARγ peroxisome proliferator activated receptor γ
TBS-T Tris-buffered saline + Tween-20
mRNA messenger RNA
RT-PCR reverse transcription polymerase chain reaction
PCR polymerase chain reaction
CCl4 carbon tetrachloride
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Figure 1. Inhibition of PI3K signaling with Ad-SMAdnPI3K reduces HSC proliferation,
migration, and collagen gene expression
(A) Each cell was cultured in proper medium containing 10% FBS for 5 days and was
transduced at a MOI of 300 with Ad-SMAdnPI3K. After 48 hr of incubation, whole cell
extracts were prepared for Western blots of HA, albumin, F4/80, CD31, αSMA and β-actin.
HC: hepatocyte, KC: Kupffer cell, LSEC: liver sinusoidal endothelial cell, HSC: hepatic
stellate cell. Results are representative of 3 independent experiments. (B) Culture-activated
HSCs were treated with PBS or transduced with Ad-βgal or Ad-dnSMAPI3K and cell
proliferation assessed after 24 hr, 48 hr, and 72 hr following stimulation with 10% FCS. P =
0.0007, P = 0.0006, P = 0.0006, respectively, compared to Ad-βgal. (C) Cell migration,
using a wound assay, was assessed in culture-activated HSCs treated with PBS in cells
transduced with Ad-βgal or Ad-SMAdnPI3K after 24 hr. P = 0.0008 compared to Ad-βgal.
(D) Co-localization of GFP (green) and HA (red) expression in HSCs isolated from
pCol9GFP-HS4,5 transgenic mice transduced with Ad-SMAdnPI3K. (E) GFP expression,
assessed by fluorescence microscopy, in HSCs isolated from pCol9GFP-HS4,5 mice 2 days
following Ad-SMAdnPI3K transduction. Original magnification, ×100 with quantification
of GFP fluorescence using phosphorimager analysis, in culture-activated HSCs 24 hr, 48 hr,
and 72 hr following PBS treatment or transduction of pCol9GFP-HS4,5 HSCs with either
Ad-βgal or Ad-SMAdnPI3K. Original magnification ×200. (F) Steady state levels of α1(I)
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collagen mRNA was determined by quantitative real-time RT-PCR. Data are expressed as
the mean ± SEM from 3 independent experiments. *P<0.01 vs. Ad-βgal transduced cells.
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Figure 2. Transduction of Ad-SMAdnPI3K induces cell death in activated HSCs and reduces
profibrotic gene expression
Hoechst 33342 (A – C) and propidium iodide (PI) (D – F) staining in culture-activated (Day
5) pCol9GFP,HS4,5 HSCs. (A, D) control cells, (B, E) cells transduced with Ad-βgal; (C,
F) cells transduced with Ad-SMAdnPI3K. After 24h cells were incubated with Hoechst (1
µg/ml) and PI (5 µg/ml) for 20 min. Figures are representative data from three independent
experiments. Original magnification ×100. (G) Culture activated (Day 5) HSCs from
pCol9GFP-HS4,5 mice were transduced with Ad-SMAdnPI3K, Ad-βgal, or no virus and
incubated for 48 hr. Steady state mRNA levels for TGF-β, αSMA, TIMP-1, CTGF, and
PPAR-γ were quantified by RT-PCR. Data are expressed as the mean ± SEM from 3
independent experiments. *P<0.05 vs. Ad-βgal transduced cells.
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Figure 3. Inhibition of PI3K activity blocks the activation of PI3K/Akt/p70S6K signaling and
reduces cyclin D1 expression
(A, B) HSCs from pCol9GFP-HS4,5 were cultured for 5 days and then transduced with
indicated adenoviruses. Cells were serum starved for 48 hr, then stimulated with 10% FBS.
Whole cell extracts were prepared at the indicated time points and Western blots for P-PI3K,
PI3K, P-Akt, Akt, P-p70S6K, P-ERK, ERK, cyclin D1, and β-actin performed. Results are
representative of 3 independent experiments.
Son et al. Page 15













Figure 4. Ad-SMAdnPI3K expresses the HA-tag in the liver and induces apoptosis in fibrotic
liver
(A) BDLs were performed on Day 0, and adenovirus administered on Day 4. Proteins were
collected from whole liver 2 days after adenoviral administration. HA-tag expression was
detected in the liver extracts by Western Blot analysis. (B) HA expression was assessed 2
days after adenoviral administration by immunofluorescent staining using a monoclonal HA
antibody (Red). Original magnification, ×200. (C) Liver cell death was assessed on Day 9
after BDL TUNEL (Day 5 after adenoviral transduction) in liver tissue. Original
magnification, ×200. (D) Immunofluorescence staining shows localization of collagen
(green), desmin (blue) and HA (red) 2 days after adenoviral administration. Original
magnification, ×200. n = 6 animals per group.
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Figure 5. Transduction of Ad-SMAdnPI3K inhibits αSMA expression in BDL-treated mice
(A) αSMA expression was examined in paraffin-embedded liver tissue of pCol9GFP-HS4,5
mice 9 days after BDL (5 days after adenoviral transduction) and 18 days after BDL (14
days after adenoviral transduction) stained using an αSMA antibody. Original magnification,
×100. (B) Quantification of αSMA stained area. (C) Western blot analysis for αSMA
expression 18 days after BDL (14 days after adenoviral transduction). n= 6 animals per
group.
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Figure 6. Administration of Ad-SMAdnPI3K attenuates liver fibrosis in BDL-treated mice
(A) Paraffin-embedded tissue of pCol9GFP-HS4,5 mice 9 days after BDL (5 days after
adenoviral transduction) and 18 days after BDL (14 days after adenoviral transduction) were
stained with Sirius red. Original magnification, ×100. (B) Quantification of Sirius red
stained area. (C) Quantitation of hepatic hydroxyproline content. (D) GFP expression in
pCol9GFP-HS4,5 mice after 9 days and 18 days following BDL (5 days and 14 days,
respectively, after adenoviral transduction) visualized by fluorescent microscopy. Sham
tissue was examined at Day 9. Original magnifications, Day 18 ×40, Sham and BDL Day 9
×100. (E) Percentage of GFP positive area, in ×100 fields, was quantified using the NIH
Image J software. (F) Steady state α1(I) collagen mRNA levels at Day 18 after BDL (n = 6
animals per group). *P<0.05 vs. Ad-βgal treated mice.
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Figure 7. Administration of Ad-SMAdnPI3K inhibits profibrotic gene expression in the livers of
BDL-treated mice, but does not affect ALT levels
(A) Steady state mRNA levels of TGF-β, αSMA, TIMP-1, and CTGF 9 days after BDL
(Day 5 after adenoviral transduction) as determined by quantitative real-time RT-PCR. Data
are presented as mean ± SEM from 6 anmials per group *P<0.05 vs. animals administered
Ad-βgal. (B) Serum ALT levels 9 days after BDL (Day 5 after adenoviral transduction; n =
6 animals per group).
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